Showing 2,421 - 2,440 results of 40,084 for search '"The Following"', query time: 0.10s Refine Results
  1. 2421
  2. 2422

    Completion of registration of risk factor variables during telephone vs on-site follow-up after myocardial infarction: a nationwide observational study in 101 199 patients from contemporary clinical practice in Sweden by Maria Bäck, Margret Leosdottir, Emil Hagström, Nermin Hadziosmanovic, Halldora Ögmundsdottir Michelsen, Mattias Ekström

    Published 2025-01-01
    “…The differences were similar at the 1-year follow-up. Self-reported measures such as smoking status, level of physical activity and current medication had a low proportion of missing data (≤2.1%) for both follow-up modalities.Conclusion Registration of secondary preventive variables was less complete at telephone consultations compared with on-site cardiac rehabilitation follow-up visits, which might indicate lower quality of care during telephone follow-up. …”
    Get full text
    Article
  3. 2423

    Re‐evaluation of citric acid esters of mono‐ and diglycerides of fatty acids (E 472c) as a food additive in foods for infants below 16 weeks of age and follow‐up of its re‐evaluation by EFSA Panel on Food Additives and Flavourings (FAF), Laurence Castle, Monica Andreassen, Gabriele Aquilina, Maria Lourdes Bastos, Polly Boon, Biagio Fallico, Reginald FitzGerald, Maria Jose Frutos Fernandez, Bettina Grasl‐Kraupp, Ursula Gundert‐Remy, Rainer Gürtler, Eric Houdeau, Marcin Kurek, Henriqueta Louro, Sabina Passamonti, Detlef Wölfle, Birgit Dusemund, Dominique Turck, Stefania Barmaz, Alexandra Tard, Ana Maria Rincon

    Published 2025-01-01
    “…Abstract Citric acid esters of mono‐ and diglycerides of fatty acids (E 472c) was re‐evaluated in 2020 by the Food Additives and Flavourings Panel (FAF Panel) along with acetic acid, lactic acid, tartaric acid, mono‐ and diacetyltartaric acid, mixed acetic and tartaric acid esters of mono‐ and diglycerides of fatty acids (E 472a,b,d,e,f). As a follow‐up to this assessment, the FAF Panel was requested to assess the safety of citric acid esters of mono‐ and diglycerides of fatty acids (E 472c) for its use as food additive in food for infants below 16 weeks of age belonging to food categories (FCs) 13.1.1 (Infant formulae as defined by Directive 2006/141/EC) and 13.1.5.1 (Dietary foods for infants for special medical purposes and special formulae for infants). …”
    Get full text
    Article
  4. 2424

    Risk of aortic aneurysm and dissection following exposure to fluoroquinolones, common antibiotics, and febrile illness using a self-controlled case series study design: Retrospective analyses of three large healthcare databases in the US. by Ajit A Londhe, Chantal E Holy, James Weaver, Sergio Fonseca, Angelina Villasis, Daniel Fife

    Published 2021-01-01
    “…<h4>Objective</h4>Recent observational studies suggest increased aortic aneurysm or dissection (AAD) risk following fluoroquinolone (FQ) exposure but acknowledge potential for residual bias from unreported patient characteristics. …”
    Get full text
    Article
  5. 2425

    Implementation of a genotyped African population cohort, with virtual follow-up: A feasibility study in the Western Cape Province, South Africa [version 2; peer review: 2 approved, 1 approved with reservations] by Robert J Wilkinson, Francisco Lakay, Nicki Tiffin, Joel A Dave, Catherine Riou, Peter Raubenheimer, Anna K Coussens, Tsaone Tamuhla, Melissa J Blumenthal, Maleeka Abrahams

    Published 2025-01-01
    “…We implemented a genotyped population cohort with virtual follow up data in a resource-constrained African environment, demonstrating feasibility for scale up and novel health discoveries through nested case-control studies.…”
    Get full text
    Article
  6. 2426
  7. 2427
  8. 2428

    Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study by Caroline J. Stone, Geeta Ahuja, Lais Lopes Almeida Gomes, Joy Poroye, Daniella Forman Faden, Lillian Xie, Rui Feng, Barbara White, Victoria P. Werth

    Published 2025-01-01
    “…Objectives: This study utilizes data from the open-label extension (OLE) phase of the lenabasum phase 2 trial and additional post-OLE follow-up data. Key aims include evaluating the drug’s long-term effectiveness and assessing disease manifestation recurrence. …”
    Get full text
    Article
  9. 2429
  10. 2430
  11. 2431
  12. 2432

    Analysis of choroidal thickness, macular thickness, peripapillary retinal nerve fiber layer thickness, and macular vascular density in children with unilateral amblyopia using swept-source optical coherence tomography and their changes following occlusion therapy by Shrutika Bhimewar, V. Kavitha, M. Heralgi Mallikarjun, B. K. Pradeep Sagar

    Published 2024-12-01
    “…CONCLUSION: CT and MT in amblyopic eyes were significantly higher. Following occlusion therapy, CT decreased in each follow-up but was not significant whereas MT decreased significantly at the last follow-up visit. …”
    Get full text
    Article
  13. 2433
  14. 2434
  15. 2435
  16. 2436

    Comparison of surgical wound infection and dehiscence following the use of two methods of nylon sutures and skin staples in staples in diabetic mellitus patients undergoing total knee arthroplasty surgery: a randomized clinical trial study by Haadiyeh Rahbari, Mohammadamin Ahmadi, Mina Amiri Doreh, Samira Mahmoudi, Parvin Ghaemmaghami, Armin Fereidouni

    Published 2025-01-01
    “…Patients were selected using a restricted random sampling method and haphazardly assigned to study groups using the permuted block randomization technique, including the suture-closed (n = 35) and staple-closed (n = 35) groups. The follow-up was 2 to 8 weeks after the surgery, evaluation of wound infection and dehiscence was performed. …”
    Get full text
    Article
  17. 2437
  18. 2438

    Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial by Ying Zhu, Jianwei Zhou, Zhigang Zhang, Jiaojiao Zhang, Jing Fei, Xiaoqing Zhu

    Published 2025-02-01
    “…The NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr(NAIVE) study aims to assess the clinical efficacy and safety of NACT in combination with tislelizumab (a monoclonal antibody for programmed cell death protein 1) for advanced EOC.Methods and analysis The NAIVE study is an investigator-initiated, prospective, single-centre, open-label, randomised controlled trial for advanced EOC with the International Federation of Gynaecology and Obstetrics (FIGO) stage IIIc with a Suidan CT score of 3 or greater or a Fagotti laparoscopic score of 8 or greater; or FIGO stage IV. …”
    Get full text
    Article
  19. 2439
  20. 2440